Tricyclic antidepressants: Effective, cheap but are they safe?

Journal of Psychopharmacology

Volumn 10, Issue SUPPL. 1, 1996, Pages 35-38

  Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Cost benefit factors; Safety; Side effects; Tricyclic antidepressants

Indexed keywords

TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CONVULSION; COST BENEFIT ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0029941069     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Alexanderson B, Price Evans D A, Sjoqvist F (1969) Steady-state plasma levels of nortriptyline in twins: influences of genetic factors of drug therapy. Br Med J 4: 764-767
2. Ashford J J (1995) Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine? Int Clin Pharmacol 9 (Suppl 4): 27-31
3. Buckley N A, Dawson A H, Whyte I M, Henry D A (1994) Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 343: 159-162
4. Hurley D M (1977) A brief note on the problem of epilepsy in antidepressant treatment. In Jukes A (ed.), Depression - the biochemical and physiological role of ludiomil. Ciba-Geigy, UK, pp. 201-203
5. Burrows G D, Maguire K P, Scoggins B A, Stevenson J, Davies B (1977) Plasma nortriptyline and clinical response - a study using changing plasma levels. Psychol Med 7: 87-91
6. Byerley W F, McConnell E J, McCabe R T, Dawson T M, Grosser B I, Wamsley J K (1988) Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin reuptake inhibitor fluoxetine. Psychopharmacology 94: 141-143
7. Dawling S, Lynn, K, Rosser R et al. (1987) The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br J Clin Pharmacol 12: 39-45
8. De Montigny C, Chaput Y, Blier P (1990) Modification of serotonergic neuronal properties by long-term treatment with serotonin reuptake blockers J Clin Psychiatr 51 (Suppl B): 4-8
9. De Vane C L, Wolin R E (1981) Excessive plasma concentrations of TCAs resulting from usual doses: a report of 6 cases. J Clin Psychiatr 42: 143-147
10. Dukes M N G, Becley L (1988) Side effects of drugs. In Blackwell B and Simon J S (eds), Antidepressant drugs, Annal 12, Vol. 2. Elsevier, Amsterdam, pp. 15-23
11. Ecketts S (1995) A commentary: measuring the health economics of depression. Hum Psychopharmacol 10: 33-37
12. Edwards J G (1985) Antidepressants and seizures: epidemiological and clinical aspects. In Trimble M R (ed.), The psychopharmacology of epilespy.Wiley, Chichester, pp. 119-139
13. Hayes P E, Kristoff C A (1986) Adverse reactions to five new antidepressants. Clin Pharmacol 5: 471-480
14. Healy D, Carney PA, O'Halloran A, Leonard B E (1985) Peripheral adrenoceptors and serotonin receptors in depression. J Affective Disord 9: 285-296
15. Henry J A, Antao C A (1992) Suicide and fatal antidepressant poisoning. Eur J Med 1: 343-348
16. Hindmarch I (1987) Three antidepressants (amitriptyline, dothiepin, fluoxetine) with and without alcohol, compared to placebo on tests of psychomotor ability related to car driving. Hum Psychopharmacol 2: 177-183
17. Jönnson B, Bebbington P E (1994) What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatr 164: 665-673
18. Leonard B E (1988) Lofepramine: pharmacology and mode of action. Int Clin Psychopharmacol 3: 25-39
19. Leonard B E (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatr 54(Suppl): 3-15
20. McWilliam C (1994) Cost-effective treatment of depression. Geriatr Med 24: 43-47
21. Montgomery S A, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9 (Suppl 4): 33-40
22. Montgomery S A, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994) Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53
23. Perel J M, Shostak M, Gram E et al. (1976) Pharmacodynamics of imipramine and clinical outcome in depressed patients. In Gottschalk L A and Merlis S (eds), Pharmacokinetics of psychoactive drugs. Spectrum Publishers, New York, pp. 75-89
24. Potter Z, Calil H M, Manian A A (1979) Hydroxylated metabolites of TCAs: preclinical assessment of activity. Biol Psychiatr 14: 601-613
25. Preskorn S H, Jerkovich G S (1990) Central nervous systems toxicity of tricyclic antidepressants: phenomenology, cause, risk factors and the role of therapeutic drug monitoring. J Clin Psychopharmacol 10: 88-95
26. Ray W A, Griffin M R, Schaffner W, Baugh D K, Melton L J (1987) Psychotropic drug use and the risk of hip fracture. New Engl J Med 316: 363-369
27. Roose S P, Glassman A H, Giardina E G, Walsh B J, Woodring S, Rigger J J (1987) Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatr 44: 273-275
28. Simpson G M, Singh H (1990) Tricyclic antidepressants In Amsterdam J D (ed.), Pharmacotherapy of depression. Marcel Dekker Inc., New York, pp. 75-91
29. Song F, Preemantle N, Sheldon T A, House A, Watson P, Long A, Mason J (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 306: 683-687
30. Swinkels J A, de Jonghe F (1995) Safety of antidepressants. Int Clin Psychopharmacol 9(Suppl 4): 19-25
31. Syssian E C, Schatzberg A F, Woods B T (1986) Maprotiline treatment in depression. Arch Gen Psychiatr 43: 86-90